Heart Failure Connect
Profile Image
Add Media
  • Saved

2yr
Preview of the 2023 Heart Failure Society of America Annual Scientific Meeting

The Heart Failure Society of America (HFSA) is hosting its Annual Scientific Meeting (ASM) at the Huntington Convention Center in Cleveland from Oct. 6 to 9, 2023.

The vision of HFSA is to reduce the burden of heart failure and provide a platform for collaboration, education, innovation, research, and advocacy to improve care in this area. The HFSA ASM is where heart failure teams gather for sessions on heart failure science, research, practical management, and networking opportunities. 

We will be covering the event for you, so check your email for highlights and a wrap-up of the conference. Click above for an exclusive preview of the event.

  • Saved

2yr
Comprehensive Diagnostic Work Up In Patients With Suspected Heart Failure And Preserved Ejection Fraction

Comprehensive Diagnostic Work Up In Patients With Suspected Heart Failure And Preserved Ejection Fraction

Source : https://www.sciencedirect.com/science/article/pii/S1109966623001847?via=ihub

Diagnosis of heart failure with preserved ejection fraction (HFpEF) can be challenging and it could require different tests, some of which are affecte...

The aim of this review is to help the clinician in diagnosing HFpEF, overcoming the diagnostic uncertainty, and in disentangling among the different underlying causes, in order to properly treat this kind of patients.

Profile Image
  • Uploads
  • Saved

2yr
SGLT2 inhibitors: an Evidence-Based Update on cardiovascular Implications - PubMed

SGLT2 inhibitors: an Evidence-Based Update on cardiovascular Implications - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37740906/

The favorable results of several clinical trials have broadened the therapeutic scenario for SGLT2 inhibitors, opening, at the same time, new challenges. Additionally, recent preclinical findings have evidenced off-target effects...

The favorable results of several clinical trials have broadened the therapeutic scenario for SGLT2 inhibitors, opening, at the same time, new challenges. Additionally, recent preclinical findings have evidenced off-target effects of SGLT2 inhibitors.

Profile Image
  • Uploads
  • Saved

2yr
Multinational cost-effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40 - PubMed

Multinational cost-effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40 - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37670496/

Empagliflozin was found to be the first targeted treatment option that is clinically effective and cost-effective for patients with HF LVEF > 40%. Prescribing empagliflozin with SoC to patients with...

Conclusions: Empagliflozin was found to be the first targeted treatment option that is clinically effective and cost-effective for patients with HF LVEF > 40%. Prescribing empagliflozin with SoC to patients with HF LVEF > 40% is expected to improve clinical outcomes and patients' quality of life and substantially below accepted WTP...

Profile Image
  • Uploads
  • Saved

2yr
Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure - PubMed

Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37629635/

Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are a relatively new class of antidiabetic drugs that have shown favorable effects in heart failure (HF) patients, irrespective of the left ventricular ejection fraction (LVEF)....

Conclusions: Dapagliflozin, an SGLT2i, was associated with an improvement in the LV and LA structural and functional echocardiographic markers in patients with HF and DM. In addition, dapagliflozin was associated with a reduction in biomarkers, such as troponin and natriuretic peptides. The abovementioned findings may explain the beneficial...

Profile Image
  • Uploads